Cargando…

Long-term outcome of stereotactic brachytherapy with temporary Iodine-125 seeds in patients with WHO grade II gliomas

BACKGROUND: This long-term retrospective analysis aimed to investigate the outcome and toxicity profile of stereotactic brachytherapy (SBT) in selected low-grade gliomas WHO grade II (LGGII) in a large patient series. METHODS: This analysis comprised 106 consecutive patients who received SBT with te...

Descripción completa

Detalles Bibliográficos
Autores principales: Watson, Juliana, Romagna, Alexander, Ballhausen, Hendrik, Niyazi, Maximilian, Lietke, Stefanie, Siller, Sebastian, Belka, Claus, Thon, Niklas, Nachbichler, Silke Birgit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7724805/
https://www.ncbi.nlm.nih.gov/pubmed/33298103
http://dx.doi.org/10.1186/s13014-020-01719-9
_version_ 1783620592631545856
author Watson, Juliana
Romagna, Alexander
Ballhausen, Hendrik
Niyazi, Maximilian
Lietke, Stefanie
Siller, Sebastian
Belka, Claus
Thon, Niklas
Nachbichler, Silke Birgit
author_facet Watson, Juliana
Romagna, Alexander
Ballhausen, Hendrik
Niyazi, Maximilian
Lietke, Stefanie
Siller, Sebastian
Belka, Claus
Thon, Niklas
Nachbichler, Silke Birgit
author_sort Watson, Juliana
collection PubMed
description BACKGROUND: This long-term retrospective analysis aimed to investigate the outcome and toxicity profile of stereotactic brachytherapy (SBT) in selected low-grade gliomas WHO grade II (LGGII) in a large patient series. METHODS: This analysis comprised 106 consecutive patients who received SBT with temporary Iodine-125 seeds for histologically verified LGGII at the University of Munich between March 1997 and July 2011. Investigation included clinical characteristics, technical aspects of SBT, the application of other treatments, outcome analyses including malignization rates, and prognostic factors with special focus on molecular biomarkers. RESULTS: For the entire study population, the 5- and 10-years overall survival (OS) rates were 79% and 62%, respectively, with a median follow-up of 115.9 months. No prognostic factors could be identified. Interstitial radiotherapy was applied in 51 cases as first-line treatment with a median number of two seeds (range 1–5), and a median total implanted activity of 21.8 mCi (range 4.2–43.4). The reference dose average was 54.0 Gy. Five- and ten-years OS and progression-free survival rates after SBT were 72% and 43%, and 40% and 23%, respectively, with a median follow-up of 86.7 months. The procedure-related mortality rate was zero, although an overall complication rate of 16% was registered. Patients with complications had a significantly larger tumor volume (p = 0.029). CONCLUSION: SBT is a minimally invasive treatment modality with a favorable outcome and toxicity profile. It is both an alternative primary treatment method as well as an adjunct to open tumor resection in selected low-grade gliomas.
format Online
Article
Text
id pubmed-7724805
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-77248052020-12-09 Long-term outcome of stereotactic brachytherapy with temporary Iodine-125 seeds in patients with WHO grade II gliomas Watson, Juliana Romagna, Alexander Ballhausen, Hendrik Niyazi, Maximilian Lietke, Stefanie Siller, Sebastian Belka, Claus Thon, Niklas Nachbichler, Silke Birgit Radiat Oncol Research BACKGROUND: This long-term retrospective analysis aimed to investigate the outcome and toxicity profile of stereotactic brachytherapy (SBT) in selected low-grade gliomas WHO grade II (LGGII) in a large patient series. METHODS: This analysis comprised 106 consecutive patients who received SBT with temporary Iodine-125 seeds for histologically verified LGGII at the University of Munich between March 1997 and July 2011. Investigation included clinical characteristics, technical aspects of SBT, the application of other treatments, outcome analyses including malignization rates, and prognostic factors with special focus on molecular biomarkers. RESULTS: For the entire study population, the 5- and 10-years overall survival (OS) rates were 79% and 62%, respectively, with a median follow-up of 115.9 months. No prognostic factors could be identified. Interstitial radiotherapy was applied in 51 cases as first-line treatment with a median number of two seeds (range 1–5), and a median total implanted activity of 21.8 mCi (range 4.2–43.4). The reference dose average was 54.0 Gy. Five- and ten-years OS and progression-free survival rates after SBT were 72% and 43%, and 40% and 23%, respectively, with a median follow-up of 86.7 months. The procedure-related mortality rate was zero, although an overall complication rate of 16% was registered. Patients with complications had a significantly larger tumor volume (p = 0.029). CONCLUSION: SBT is a minimally invasive treatment modality with a favorable outcome and toxicity profile. It is both an alternative primary treatment method as well as an adjunct to open tumor resection in selected low-grade gliomas. BioMed Central 2020-12-09 /pmc/articles/PMC7724805/ /pubmed/33298103 http://dx.doi.org/10.1186/s13014-020-01719-9 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Watson, Juliana
Romagna, Alexander
Ballhausen, Hendrik
Niyazi, Maximilian
Lietke, Stefanie
Siller, Sebastian
Belka, Claus
Thon, Niklas
Nachbichler, Silke Birgit
Long-term outcome of stereotactic brachytherapy with temporary Iodine-125 seeds in patients with WHO grade II gliomas
title Long-term outcome of stereotactic brachytherapy with temporary Iodine-125 seeds in patients with WHO grade II gliomas
title_full Long-term outcome of stereotactic brachytherapy with temporary Iodine-125 seeds in patients with WHO grade II gliomas
title_fullStr Long-term outcome of stereotactic brachytherapy with temporary Iodine-125 seeds in patients with WHO grade II gliomas
title_full_unstemmed Long-term outcome of stereotactic brachytherapy with temporary Iodine-125 seeds in patients with WHO grade II gliomas
title_short Long-term outcome of stereotactic brachytherapy with temporary Iodine-125 seeds in patients with WHO grade II gliomas
title_sort long-term outcome of stereotactic brachytherapy with temporary iodine-125 seeds in patients with who grade ii gliomas
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7724805/
https://www.ncbi.nlm.nih.gov/pubmed/33298103
http://dx.doi.org/10.1186/s13014-020-01719-9
work_keys_str_mv AT watsonjuliana longtermoutcomeofstereotacticbrachytherapywithtemporaryiodine125seedsinpatientswithwhogradeiigliomas
AT romagnaalexander longtermoutcomeofstereotacticbrachytherapywithtemporaryiodine125seedsinpatientswithwhogradeiigliomas
AT ballhausenhendrik longtermoutcomeofstereotacticbrachytherapywithtemporaryiodine125seedsinpatientswithwhogradeiigliomas
AT niyazimaximilian longtermoutcomeofstereotacticbrachytherapywithtemporaryiodine125seedsinpatientswithwhogradeiigliomas
AT lietkestefanie longtermoutcomeofstereotacticbrachytherapywithtemporaryiodine125seedsinpatientswithwhogradeiigliomas
AT sillersebastian longtermoutcomeofstereotacticbrachytherapywithtemporaryiodine125seedsinpatientswithwhogradeiigliomas
AT belkaclaus longtermoutcomeofstereotacticbrachytherapywithtemporaryiodine125seedsinpatientswithwhogradeiigliomas
AT thonniklas longtermoutcomeofstereotacticbrachytherapywithtemporaryiodine125seedsinpatientswithwhogradeiigliomas
AT nachbichlersilkebirgit longtermoutcomeofstereotacticbrachytherapywithtemporaryiodine125seedsinpatientswithwhogradeiigliomas